References
Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50(2): 99–110
Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45(8): 755–73
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37(3): 840–51
Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the Saline versus Albumin Fluid Evaluation (SAFE) study. BMJ 2006; 333(7577): 1044
Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacokinet 1978; 3(2): 144–54
Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983; 11(3): 233–8
Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 2003; 17(3): 599–613
Goldstein A. The interactions of drugs and plasma proteins. J Pharmacol Exp Ther 1949; 95 Pt 2 (4): 102–65
Joynt GM, Lipman J, Gomersall D, et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001; 47(4): 421–9
Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59(2): 277–84
Brink AJ, Richards GA, Schillack V, et al. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 2009; 33(5): 432–6
Janicke DM, Cafarell RF, Parker SW, et al. Pharmacokinetics of aztreonam in patients with Gram-negative infections. Antimicrob Agents Chemother 1985; 27(1): 16–20
Friedrich LV, White RL, Kays MB, et al. Aztreonam pharmacokinetics in burn patients. Antimicrob Agents Chemother 1991; 35(1): 57–61
Peter JD, Jehl F, Pottecher T, et al. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob Agents Chemother 1993; 37(3): 501–6
MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998; 20(5): 473–7
Rights and permissions
About this article
Cite this article
Consider adjusting the dose of antibacterials in critically ill patients with hypoalbuminaemia. Drugs Ther. Perspect 27, 23–25 (2011). https://doi.org/10.2165/11208040-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11208040-000000000-00000